Back To: Home : Featured Technology : Stem Cell

CLICK HERE FOR WHAT'S NEW IN:
 

BioTime, USCN sign option, distribution agreements
February 2012
SHARING OPTIONS:

ALAMEDA, Calif.BioTime Inc. has announced agreements with USCN Life Science Inc. (USCN) that grant BioTime an option to license USCN's antibody-producing cell lines and certain related technology that BioTime and its subsidiary OncoCyte Corp. can use for the large-scale manufacture of the antibody components of PanC-Dx. A novel diagnostic technology, PanC-Dx was discovered at BioTime and OncoCyte and is intended to detect the presence of various cancers, including breast, colon, lung, stomach, uterine and bladder cancers. BioTime and USCN also signed a distribution agreement that grants BioTime and its subsidiaries the right to market more than 4,000 diverse ELISA and CLIA kits for detecting a wide array of proteins for the stem cell research market, which BioTime intends to sell through its subsidiary LifeMap Sciences Inc. in 2012.  


Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.